| Lenalidomide after stem-cell transplantation for multiple myeloma PL McCarthy, K Owzar, CC Hofmeister, DD Hurd, H Hassoun, ... New England Journal of Medicine 366 (19), 1770-1781, 2012 | 1328 | 2012 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 … JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... The Lancet 398 (10297), 314-324, 2021 | 906 | 2021 |
| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 717 | 2020 |
| Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma S Kumar, I Flinn, PG Richardson, P Hari, N Callander, SJ Noga, ... Blood, The Journal of the American Society of Hematology 119 (19), 4375-4382, 2012 | 558 | 2012 |
| Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ... Leukemia 33 (9), 2266-2275, 2019 | 497 | 2019 |
| Reversible posterior leukoencephalopathy syndrome and bevacizumab C Ozcan N Engl J Med 354, 980-982, 2006 | 450 | 2006 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Current use of and trends in hematopoietic cell transplantation in the United States A D'Souza, C Fretham, SJ Lee, M Arora, J Brunner, S Chhabra, S Devine, ... Biology of Blood and Marrow Transplantation 26 (8), e177-e182, 2020 | 416 | 2020 |
| Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial NN Shah, BD Johnson, D Schneider, F Zhu, A Szabo, CA Keever-Taylor, ... Nature medicine 26 (10), 1569-1575, 2020 | 352 | 2020 |
| Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies ML Sorror, BM Sandmaier, BE Storer, GN Franke, GG Laport, ... Jama 306 (17), 1874-1883, 2011 | 333 | 2011 |
| Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102 … A Krishnan, MC Pasquini, B Logan, EA Stadtmauer, DH Vesole, E Alyea, ... The lancet oncology 12 (13), 1195-1203, 2011 | 332 | 2011 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 323 | 2017 |
| Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an … SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, ... The Lancet Oncology 15 (13), 1503-1512, 2014 | 322 | 2014 |
| PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD BM Haverkos, D Abbott, M Hamadani, P Armand, ME Flowers, ... Blood, The Journal of the American Society of Hematology 130 (2), 221-228, 2017 | 274 | 2017 |
| Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation R Storb, B Gyurkocza, BE Storer, ML Sorror, K Blume, D Niederwieser, ... Journal of Clinical Oncology 31 (12), 1530, 2013 | 263 | 2013 |
| Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma SM Smith, LJ Burns, K van Besien, J LeRademacher, W He, TS Fenske, ... Journal of clinical oncology 31 (25), 3100, 2013 | 261 | 2013 |
| Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up T Martin, SZ Usmani, JG Berdeja, M Agha, AD Cohen, P Hari, D Avigan, ... Journal of Clinical Oncology 41 (6), 1265, 2023 | 254 | 2023 |
| Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial EA Stadtmauer, MC Pasquini, B Blackwell, P Hari, A Bashey, S Devine, ... Journal of clinical oncology 37 (7), 589, 2019 | 247 | 2019 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant … N Ghosh, R Karmali, V Rocha, KW Ahn, A DiGilio, PN Hari, V Bachanova, ... Journal of Clinical Oncology 34 (26), 3141, 2016 | 246 | 2016 |
